Fairchem Organics Limited

Fairchem Organics reported a challenging Q3 FY26 with revenue from operations at ₹100 crores, marking a 12% year-on-year decline. EBITDA for the quarter stood at ₹4 crores, resulting in an EBITDA margin of 4.2%. The adjusted net profit after tax was ₹0.6 crores (60 lakhs), with a PAT margin of 0.6%. For the nine-month period, revenue was ₹343 crores (an 18% decline), and EBITDA was ₹14 crores (a 65% decline), yielding an EBITDA margin of 3.97%. Domestic sales contributed 91% of the total revenue.

The company faced significant external headwinds^🌐, including lower off-take from the paint segment and discontinuation of key product exports to US markets. Elevated raw material prices, exacerbated by a 16.5% custom duty, and the availability of lower-priced imports from China, limited the company's ability to pass on cost increases. The dimer acid segment, in particular, remained under pressure due to aggressive pricing from Chinese suppliers and an unchanged 7.5% import duty on imports, leading to 'very marginal' profitability.

Despite near-term challenges, Fairchem is implementing several strategic initiatives. These include undertaking in-depth energy audits for energy saving, trials with domestic catalysts to reduce reliance on imported ones, and developing newer products from existing streams for diverse applications. Management expressed cautious optimism, believing the worst quarter is behind them and expecting volume and value growth every quarter.

The company aims to significantly increase its export mix from the current 9% to as high as 50% of total turnover. This growth is expected to be driven by the opening of the US market for isosteric acid and dimer fatty acid due to new treaties, and the potential removal of export incentives for Chinese dimer players, which could lead to a 12-13% price hike. The isosteric business is specifically expected to be 'back on track' within the next six months.

The animal feed plant is ready and awaiting GMP certifications, with production anticipated to commence by Q3 of the next fiscal year. This product represents a forward integration of the palmitic acid stream and is expected to offer better margins. The company plans to start with a small capacity, learning from past experiences that buyer approvals for new products can take 2-3 years. Another new product, whose name remains undisclosed, is also expected to go into production by Q3 of the next fiscal year, utilizing reserved capacity.

Management confirmed that there is no pressure on cash flow, and the company's current capacity utilization is approximately 55%. This existing capacity is sufficient to support the projected volume increase over the next two years, eliminating the need for further CAPEX. A recent buyback was undertaken as a strategy to increase promoter holding, reflecting confidence in the company's long-term prospects without impacting liquidity for growth initiatives.